48
Systemic sclerosis (SSc) Systemic sclerosis (SSc) Limited cutaneous SSc Diffuse cutaneous SSc Overlap syndromes Mixed connective tissue disease

Scleroderma

Embed Size (px)

Citation preview

Page 1: Scleroderma

Systemic sclerosis (SSc)

Systemic sclerosis (SSc)

Limited cutaneous SScDiffuse cutaneous SSc

Overlap syndromes

Mixed connective tissue disease

Page 2: Scleroderma

Pathophysiology• autoimmune dysfunction• T cells accumulate in the skin• secrete cytokines and other proteins that stimulate collagen

deposition.• Stimulation of the fibroblast • transforming growth factor (TGFβ)• connective tissue growth factor (CTGF) • Damage to endothelium is an early abnormality in the development

of scleroderma

Page 3: Scleroderma

• due to collagen accumulation by fibroblasts, although direct alterations by cytokines, platelet adhesion and a type II hypersensitivity reaction• Increased endothelin and decreased vasodilation

Page 4: Scleroderma
Page 5: Scleroderma

Epidemiology• SSc is an acquired sporadic disease • Like other connective tissue diseases, SSc shows a female

predominance • most pronounced in the childbearing years and declines after

menopause. • SSc can present at any age• the most common age of onset for both limited and diffuse cutaneous

forms is in the range of 30–50 years.

Page 6: Scleroderma
Page 7: Scleroderma
Page 8: Scleroderma
Page 9: Scleroderma
Page 10: Scleroderma
Page 11: Scleroderma
Page 12: Scleroderma
Page 13: Scleroderma
Page 14: Scleroderma
Page 15: Scleroderma
Page 16: Scleroderma
Page 17: Scleroderma
Page 18: Scleroderma
Page 19: Scleroderma
Page 20: Scleroderma
Page 21: Scleroderma

S

Page 22: Scleroderma
Page 23: Scleroderma
Page 24: Scleroderma
Page 25: Scleroderma
Page 26: Scleroderma
Page 27: Scleroderma
Page 28: Scleroderma
Page 29: Scleroderma
Page 30: Scleroderma
Page 31: Scleroderma
Page 32: Scleroderma
Page 33: Scleroderma
Page 34: Scleroderma
Page 35: Scleroderma
Page 36: Scleroderma
Page 37: Scleroderma
Page 38: Scleroderma
Page 39: Scleroderma

scleroderma renal crisis. • The most important clinical complication of scleroderma involving the kidney

• Symptoms• malignant hypertension• azotemia • microangiopathic hemolytic anemia • high blood pressure• hematuria • proteinuria

• Treatment for scleroderma renal crisis include ACE inhibitors.

Page 40: Scleroderma
Page 41: Scleroderma

Diagnosis• clinical suspicion• presence of autoantibodies (specifically anti-centromere and anti-

scl70/anti-topoisomerase antibodies) • Of the antibodies, 90% have a detectable ANA. • Anti-centromere antibody is more common in the limited form (80-

90%) than in the diffuse form (10%)• anti-scl70 is more common in the diffuse form (30-40%)

Page 42: Scleroderma
Page 43: Scleroderma
Page 44: Scleroderma
Page 45: Scleroderma
Page 46: Scleroderma

MCTDMIXED CONNECTIVE TISSUE DISORDERS• an autoimmune disease• Signs and symptoms• combines features of scleroderma, myositis, systemic lupus

erythematosus, and rheumatoid arthritis• thus considered an overlap syndrome.

Page 47: Scleroderma

• MCTD commonly causes:

• joint pain/swelling,• malaise,• Raynaud phenomenon,• muscle inflammation, and• sclerodactyly (thickening of the skin of the pads of the fingers)

Page 48: Scleroderma

Diagnosis• positive, speckled anti-nuclear antibody and an anti-U1-RNP antibody.

• Cause• It has been associated with HLA-DR4

• Prognosis• In spite of prednisone treatment, this disease is progressive

• Most deaths from MCTD are due to heart failure caused by Pulmonary Arterial Hypertension (PAH).